BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37897252)

  • 21. Genomic Markers in Prostate Cancer Decision Making.
    Cucchiara V; Cooperberg MR; Dall'Era M; Lin DW; Montorsi F; Schalken JA; Evans CP
    Eur Urol; 2018 Apr; 73(4):572-582. PubMed ID: 29129398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator.
    Parekh S; Ratnani P; Falagario U; Lundon D; Kewlani D; Nasri J; Dovey Z; Stroumbakis D; Ranti D; Grauer R; Sobotka S; Pedraza A; Wagaskar V; Mistry L; Jambor I; Lantz A; Ettala O; Stabile A; Taimen P; Aronen HJ; Knaapila J; Perez IM; Gandaglia G; Martini A; Picker W; Haug E; Cormio L; Nordström T; Briganti A; Boström PJ; Carrieri G; Haines K; Gorin MA; Wiklund P; Menon M; Tewari A
    Eur Urol Open Sci; 2022 Jul; 41():45-54. PubMed ID: 35813258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
    Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
    Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Utility of Negative Multiparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer and Clinically Significant Prostate Cancer.
    Wagaskar VG; Levy M; Ratnani P; Moody K; Garcia M; Pedraza AM; Parekh S; Pandav K; Shukla B; Prasad S; Sobotka S; Haines K; Punnen S; Wiklund P; Tewari A
    Eur Urol Open Sci; 2021 Jun; 28():9-16. PubMed ID: 34337520
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study.
    Emmett L; Buteau J; Papa N; Moon D; Thompson J; Roberts MJ; Rasiah K; Pattison DA; Yaxley J; Thomas P; Hutton AC; Agrawal S; Amin A; Blazevski A; Chalasani V; Ho B; Nguyen A; Liu V; Lee J; Sheehan-Dare G; Kooner R; Coughlin G; Chan L; Cusick T; Namdarian B; Kapoor J; Alghazo O; Woo HH; Lawrentschuk N; Murphy D; Hofman MS; Stricker P
    Eur Urol; 2021 Dec; 80(6):682-689. PubMed ID: 34465492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Not All Multiparametric Magnetic Resonance Imaging-targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection of Clinically Significant Prostate Cancer.
    Stabile A; Dell'Oglio P; Gandaglia G; Fossati N; Brembilla G; Cristel G; Dehò F; Scattoni V; Maga T; Losa A; Gaboardi F; Cardone G; Esposito A; De Cobelli F; Del Maschio A; Montorsi F; Briganti A
    Eur Urol Oncol; 2018 Jun; 1(2):120-128. PubMed ID: 31100235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Using clinical parameters to predict prostate cancer and reduce the unnecessary biopsy among patients with PSA in the gray zone.
    Liu J; Dong B; Qu W; Wang J; Xu Y; Yu S; Zhang X
    Sci Rep; 2020 Mar; 10(1):5157. PubMed ID: 32198373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study.
    Govers TM; Hessels D; Vlaeminck-Guillem V; Schmitz-Dräger BJ; Stief CG; Martinez-Ballesteros C; Ferro M; Borque-Fernando A; Rubio-Briones J; Sedelaar JPM; van Criekinge W; Schalken JA
    Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):101-109. PubMed ID: 30127462
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Yang J; Li J; Xiao L; Zhou M; Fang Z; Cai Y; Tang Y; Hu S
    Cancer Imaging; 2023 Sep; 23(1):81. PubMed ID: 37667341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of an urinary biomarker panel in combination with MRI for prostate cancer diagnosis.
    Govers TM; Resnick MJ; Rastinehad AR; Caba L; Groskopf J; van Criekinge W
    World J Urol; 2023 Jun; 41(6):1527-1532. PubMed ID: 37133554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of a nomogram combining multiparametric magnetic resonance imaging and PSA-related parameters to enhance the detection of clinically significant cancer across different region.
    Zhou Z; Liang Z; Zuo Y; Zhou Y; Yan W; Wu X; Ji Z; Li H; Hu M; Ma L
    Prostate; 2022 Apr; 82(5):556-565. PubMed ID: 35098557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The diagnostic accuracy of multiparametric magnetic resonance imaging before biopsy in the detection of prostate cancer.
    Otti VC; Miller C; Powell RJ; Thomas RM; McGrath JS
    BJU Int; 2019 Jan; 123(1):82-90. PubMed ID: 29804315
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of clinically significant prostate cancer by transperineal multiparametric magnetic resonance imaging-ultrasound fusion targeted prostate biopsy in smaller prostates.
    Dahl DM; Kim MM; Wu S; Lin SX; Crotty RK; Cornejo KM; Harisinghani MG; Feldman AS; Wu CL
    Urol Oncol; 2022 Oct; 40(10):451.e9-451.e14. PubMed ID: 36008257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Using the prostate imaging reporting and data system version 2 (PI-RIDS v2) to detect prostate cancer can prevent unnecessary biopsies and invasive treatment.
    Liu C; Liu SL; Wang ZX; Yu K; Feng CX; Ke Z; Wang L; Zeng XY
    Asian J Androl; 2018; 20(5):459-464. PubMed ID: 29667616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI.
    Costa DN; Jia L; Subramanian N; Xi Y; Rofsky NM; Recchimuzzi DZ; de Leon AD; Arraj P; Pedrosa I
    AJR Am J Roentgenol; 2021 Aug; 217(2):395-403. PubMed ID: 32876473
    [No Abstract]   [Full Text] [Related]  

  • 36. Diagnostic Accuracy of Microultrasound in Patients with a Suspicion of Prostate Cancer at Magnetic Resonance Imaging: A Single-institutional Prospective Study.
    Lughezzani G; Maffei D; Saita A; Paciotti M; Diana P; Buffi NM; Colombo P; Elefante GM; Hurle R; Lazzeri M; Guazzoni G; Casale P
    Eur Urol Focus; 2021 Sep; 7(5):1019-1026. PubMed ID: 33069624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting the Need for Biopsy to Detect Clinically Significant Prostate Cancer in Patients with a Magnetic Resonance Imaging-detected Prostate Imaging Reporting and Data System/Likert ≥3 Lesion: Development and Multinational External Validation of the Imperial Rapid Access to Prostate Imaging and Diagnosis Risk Score.
    Peters M; Eldred-Evans D; Kurver P; Falagario UG; Connor MJ; Shah TT; Verhoeff JJC; Taimen P; Aronen HJ; Knaapila J; Montoya Perez I; Ettala O; Stabile A; Gandaglia G; Fossati N; Martini A; Cucchiara V; Briganti A; Lantz A; Picker W; Haug ES; Nordström T; Tanaka MB; Reddy D; Bass E; van Rossum PSN; Wong K; Tam H; Winkler M; Gordon S; Qazi H; Boström PJ; Jambor I; Ahmed HU
    Eur Urol; 2022 Nov; 82(5):559-568. PubMed ID: 35963650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Detection of Prostate Cancer with Magnetic Resonance Imaging-Targeted Prostate Biopsies is Superior with the Transperineal vs the Transrectal Approach. A European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi-Institutional Study.
    Zattoni F; Marra G; Kasivisvanathan V; Grummet J; Nandurkar R; Ploussard G; Olivier J; Chiu PK; Valerio M; Gontero P; Guo H; Zhuang J; Barletta F; Leni R; Frydenberg M; Moon D; Hanegbi U; Landaumailto A; Snow R; Apfelbeck M; Kretschmer A; van den Bergh R; Novara G; Briganti A; Dal Moro F; Gandaglia G
    J Urol; 2022 Oct; 208(4):830-837. PubMed ID: 36082555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series.
    Barletta F; Stabile A; Mazzone E; Brembilla G; Sorce G; Pellegrino F; Scuderi S; Cannoletta D; Cirulli GO; Cucchiara V; Gandaglia G; De Cobelli F; Montorsi F; Briganti A
    Urol Oncol; 2022 Mar; 40(3):103.e17-103.e24. PubMed ID: 34688534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of risk factors for determining the need for prostate biopsy in patients with negative MRI.
    Liang L; Qi F; Cheng Y; Zhang L; Cao D; Cheng G; Hua L
    Sci Rep; 2021 Mar; 11(1):6048. PubMed ID: 33723287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.